Back to search results
NCT07057583

A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells

Enrolling by Invitation
Not specifiedAges 18+Observational
Mayo Clinic
~40 participants
Updated 2025-12-19 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs)
Measured over Up to 30 days

Conditions

Monoclonal Gammopathy of Undetermined Significance (MGUS)
Non-IgM Monoclonal Gammopathy of Undetermined Significance

Explore related trials

Non-IgM Monoclonal Gammopathy of Undetermined Significance

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Wilson I. Gonsalves, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All Participants:
At least age 18 years or older
Able to provide informed consent
MGUS Cohort:
International Myeloma Working Group (IMWG) criteria for the diagnosis of non-IgM MGUS

Exclusion

All Participants:
Unable to provide consent
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \>1
Prior history of adverse events with conscious sedation
Ongoing use of immunosuppressive medications
All known pregnant and lactating women will be excluded

What this trial measures

  • Extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs)Up to 30 days

    Assessed by evaluating blood and bone marrow aspirate samples for mean 13Carbon (13C) percentage enrichment of the mass isotopomers of interest of at least 6 (i.e. the difference between a mean 13C percentage enrichment of a particular mass isotopomer is 12% in the MGUS group and 6% in the healthy participant group or vice versa) using a 2-group t-test with a 2-sided significance level of 0.01.